107 related articles for article (PubMed ID: 33129609)
41. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
42. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.
Pittman PR; Hack D; Mangiafico J; Gibbs P; McKee KT; Friedlander AM; Sjogren MH
Vaccine; 2002 May; 20(16):2107-15. PubMed ID: 11972980
[TBL] [Abstract][Full Text] [Related]
43. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
[TBL] [Abstract][Full Text] [Related]
44. Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.
Schiffer JM; McNeil MM; Quinn CP
Expert Rev Vaccines; 2016 Sep; 15(9):1151-62. PubMed ID: 26942655
[TBL] [Abstract][Full Text] [Related]
45. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
Front Immunol; 2018; 9():562. PubMed ID: 29616046
[TBL] [Abstract][Full Text] [Related]
46. Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure.
Gallovic MD; Schully KL; Bell MG; Elberson MA; Palmer JR; Darko CA; Bachelder EM; Wyslouzil BE; Keane-Myers AM; Ainslie KM
Adv Healthc Mater; 2016 Oct; 5(20):2617-2627. PubMed ID: 27594343
[TBL] [Abstract][Full Text] [Related]
47. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
48. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
[TBL] [Abstract][Full Text] [Related]
49. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
[TBL] [Abstract][Full Text] [Related]
50. Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.
Jones RM; Burke M; Dubose D; Chichester JA; Manceva S; Horsey A; Streatfield SJ; Breit J; Yusibov V
Vaccine; 2017 Oct; 35(41):5463-5470. PubMed ID: 28117174
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
Berthold I; Pombo ML; Wagner L; Arciniega JL
Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
[TBL] [Abstract][Full Text] [Related]
52. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH
PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820
[TBL] [Abstract][Full Text] [Related]
53. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
54. Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.
Oscherwitz J; Feldman D; Yu F; Cease KB
Vaccine; 2015 Jan; 33(3):430-6. PubMed ID: 25454087
[TBL] [Abstract][Full Text] [Related]
55. Progress towards the Development of a NEAT Vaccine for Anthrax II: Immunogen Specificity and Alum Effectiveness in an Inhalational Model.
Jelinski J; Terwilliger A; Green S; Maresso A
Infect Immun; 2020 Jul; 88(8):. PubMed ID: 32393506
[No Abstract] [Full Text] [Related]
56. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
57. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
[TBL] [Abstract][Full Text] [Related]
58. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
[TBL] [Abstract][Full Text] [Related]
59. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
60. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
